Clinical Trial Update: Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the optimal duration of low molecular weight heparin in cancer patients with deep vein thrombosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Deep Vein Thrombosis

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Azienda Ospedaliera Universitaria Policlinico | Conditions: Deep Vein Thrombosis, Cancer | Phase 4 | Status: UNKNOWN